From Patient Sample to Actionable Antibiotic Recommendations in Under 90 Minutes instead of 72 hours. Empowering clinicians with point-of-care genomic intelligence.
# Monitoring Oxford Nanopore Stream...
Status: Active Python watch_directory live
🎯 Pipeline Output Sample:
• Species Identified: S. aureus (MRSA)
• Gene Profile Detected: mecA, blaKPC
• Prediction Engine: ESM-2 + XGBoost
• MIC Profile Generated: 30+ Antibiotic Classes
A patient in the ICU is dying of a severe infection. Clinicians face an impossible choice: wait 3 days for standard culture labs, or guess empirically with broad-spectrum therapeutics.
Annual Global AMR Deaths
Projected Deaths by 2050
Standard Culture Latency
Empirical Rx Without Confirmation
India's first AI-driven Antimicrobial Resistance (AMR) and rare disease point-of-care diagnostic engine.
Leverages Oxford Nanopore MinION devices to process raw electrical squiggle signals immediately on-site, converting them rapidly into sequence strings data streams.
Utilizes ESM-2 and custom XGBoost regressors to decode resistance genes against global curated repositories (CARD/PATRIC) with 85%+ accuracy on target validation benchmarks.
Runs 100% locally on a cost-effective consumer GPU (RTX 5070). Fully compliant with India’s DPDP and UAE’s PDPL health privacy acts — no clinical data egress to external clouds.
Patient blood, sputum or urine sample passed through an Oxford Nanopore device yielding raw .fast5 / .pod5 signals.
Real-time local GPU pipeline basecaller maps signal fluctuations directly to standard genomic string character formatting (.fastq).
Identifies pathogen species instantly and generates predictive MIC profiles across 30+ core antibiotic treatment compounds.
Pushes precise diagnostic records directly to hospital HIS dashboards via fully compatible FHIR interfaces.
Deploying via Hub71+ Life Sciences to bridge directly into Seha, DHA, and Cleveland Clinic Abu Dhabi hospital diagnostic purchasing loops.
Targeting private medical infrastructures with scaling milestones tracking towards ₹52 Crore revenue by Year 5 via diagnostic fees and hospital SaaS models.
Structured CE Marking strategy designed and managed through our dedicated Netherlands co-founding pathways.
We are building the world's most defensible, real-time microbial resistance information asset while saving lives at the point of clinical interaction. Join us.